Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2Bi-armed T Cells for Neuroblastoma and GD2-Positive Tumors
NCT02173093Phase 2Unknown
- Sponsor
- University of Virginia
- Start
- Nov 2014
- Primary completion
- Dec 2019
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of GD2Bi-aATC in neuroblastoma, osteosarcoma (OS), solid tumor, sponsored by University of Virginia. Status: unknown.
02
Drugs
GD2Bi-aATC
03
Conditions
neuroblastomaosteosarcoma (OS)solid tumor
Beyond the preview
Go deeper on NCT02173093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173093.